FIELD: medicine; pharmaceuticals.
SUBSTANCE: described is an aqueous pharmaceutical composition for treating central nervous system disorders for parenteral administration. Composition contains allopregnanolone in a concentration of 1 to 5 mg / ml, sulpho butyl ether of beta-cyclodextrin in a concentration of 200 to 300 mg / ml and citrate buffer. Composition has pH from 5 to 9.
EFFECT: pharmaceutical composition of allopregnanolone according to the invention is characterised by high stability over several months.
8 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2667010C2 |
| METHODS OF TREATMENT OF EPILEPSY OR STATUS EPILEPTICUS | 2013 |
|
RU2824132C2 |
| NEUROACTIVE STEROID SOLUTIONS AND METHODS FOR ADMINISTRATION | 2016 |
|
RU2803464C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND METHODS OF USING THEM | 2015 |
|
RU2731000C2 |
| ANAESTHETIC COMPOSITION | 2011 |
|
RU2574022C2 |
| PARENTERAL LIQUID PREPARATION INCLUDING CARBAMATE COMPOUND | 2017 |
|
RU2761041C2 |
| PHARMACEUTICAL COMPOSITION | 2003 |
|
RU2313346C2 |
| COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | 2018 |
|
RU2787621C2 |
| INHALATION COMPOSITION CONTAINING SULFOALKYL ETHER | 2004 |
|
RU2388462C2 |
